Company intelligence / Profile preview
Introgen Therapeutics, Inc.
Austin, Texas, United Statesmedia.corporate-ir.net ↗
- Ownership
- Private
- Development stage
- Phase 3
01
Overview
Introgen was a pioneer in gene therapy for oncology, with its lead product ADVEXIN® targeting the p53 pathway. ADVEXIN showed increased survival and tumor control in recurrent head and neck cancer patients across multiple global Phase I–III trials. The company submitted a BLA to the FDA and an MAA to the EMEA for this indication but faced regulatory setbacks. Financial difficulties led to Chapter 11 bankruptcy filing in late 2008.[1][5]
- Therapeutic areas
- Oncology
- Modalities
- Gene therapy (adenoviral vectors)Molecular therapeuticsImmunotherapiesVaccines[8][4]Nano-particle tumor suppressor therapies[8]
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Request access →03
Partnerships
Aventis Pharma SA invested $25 million via preferred shares purchasecollaborations with National Institutes of Health/NCIacademic partnerships with University of Texas M.D. Anderson Cancer Center, Columbia University.[2][4]
Beyond the preview
Go deeper on Introgen Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Introgen Therapeutics, Inc..